Prometheus Biosciences, Inc.

Cedars-sinai Medical Center

Dr. Falk Pharma Gmbh

Cindy T Dickerson

Jeffry Dean Watkins

Stephan R Targan

Janine Bilsborough

Patricia McNeeley

Bradley Henkle

Matthew Reissman

J Monty Watkins

Rafael Rojas

Janine M Bilsborough

Dermot P Mcgovern

Alka Potdar

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

Methods and systems for selection and treatment of patients with inflammatory diseases

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof

Optimized anti-TL1A antibodies

Growing community of inventors

Encinitas, CA, United States of America

Cindy T Dickerson